Vor Biopharma Inc (VOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.254x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.25 Million) by net assets ($-150.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VOR net asset quality score to measure how much of total assets are equity-financed.
Vor Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Vor Biopharma Inc to evaluate the quality of earnings relative to operating cash generation.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKAN Group AG
SW:SKAN
|
0.312x |
|
Fujian Aonong Biological Technology Group Incorporation Ltd
SHG:603363
|
0.008x |
|
SUPERLOOP LTD
F:9SL
|
N/A |
|
Three Squirrels
SHE:300783
|
0.001x |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
N/A |
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
0.275x |
|
Oriental Holdings Bhd
KLSE:4006
|
0.060x |
|
MCEWEN MINING INC.
F:US8
|
0.006x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Vor Biopharma Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-164.31 Million | $-142.71 Million | 0.869x | +184.24% |
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more